Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00628251




Registration number
NCT00628251
Ethics application status
Date submitted
26/02/2008
Date registered
5/03/2008
Date last updated
5/12/2019

Titles & IDs
Public title
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Scientific title
A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-based Chemotherapy
Secondary ID [1] 0 0
D0810C00012
Universal Trial Number (UTN)
Trial acronym
ICEBERG 3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ovarian Neoplasms 0 0
Condition category
Condition code
Cancer 0 0 0 0
Ovarian and primary peritoneal

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - AZD2281
Treatment: Drugs - Liposomal Doxorubicin
Treatment: Drugs - AZD2281

Experimental: 1 - AZD2281 Oral 200 mg BID

Active comparator: 2 - Liposomal Doxorubicin

Experimental: 3 - AZD2281 Oral 400 mg BID


Treatment: Drugs: AZD2281
400mg Oral twice daily

Treatment: Drugs: Liposomal Doxorubicin
50mg/m2 Monthly Intravenous

Treatment: Drugs: AZD2281
200mg oral twice daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS)
Timepoint [1] 0 0
Tumour assessment was to be assessed at screening, every 8 weeks during the study and at the withdrawal visit, up to 56 weeks. (Data cut-off for primary analysis of PFS: 15 September 2009)
Secondary outcome [1] 0 0
Objective Response Rate (ORR)
Timepoint [1] 0 0
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Secondary outcome [2] 0 0
Disease Control Rate
Timepoint [2] 0 0
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Secondary outcome [3] 0 0
Overall Duration of Response
Timepoint [3] 0 0
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Secondary outcome [4] 0 0
Best Percentage Change in Tumour Size
Timepoint [4] 0 0
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Secondary outcome [5] 0 0
Best Percentage Change From Baseline in CA-125 Levels
Timepoint [5] 0 0
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Secondary outcome [6] 0 0
Confirmed RECIST Response and/or CA-125 Response
Timepoint [6] 0 0
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Secondary outcome [7] 0 0
Overall Survival (OS)
Timepoint [7] 0 0
At the time of the cut-off for the final analysis of overall survival (30 April 2010)
Secondary outcome [8] 0 0
Best Quality of Life (QoL) Response for Trial Outcome Index (TOI)
Timepoint [8] 0 0
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Secondary outcome [9] 0 0
Best QoL Response for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O)
Timepoint [9] 0 0
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Secondary outcome [10] 0 0
Best QoL Response for FACT-O Symptom Index (FOSI)
Timepoint [10] 0 0
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)

Eligibility
Key inclusion criteria
* Advanced ovarian cancer with positive BRCA1 or BRCA2 status
* Progressive or recurrent disease after platinum-based chemotherapy
* Measurable disease by RECIST
Minimum age
18 Years
Maximum age
130 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Previous anthracycline treatment
* Brain metastases
* Less than 28 days since last treatment used to treat the disease
* Considered a poor medical risk due to a serious uncontrolled disorder

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/07/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/09/2018
Sample size
Target
Accrual to date
Final
97
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - East Melbourne
Recruitment hospital [2] 0 0
Research Site - Melbourne, Parkville
Recruitment hospital [3] 0 0
Research Site - Randwick
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment postcode(s) [2] 0 0
VIC 3050 - Melbourne, Parkville
Recruitment postcode(s) [3] 0 0
2031 - Randwick
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Massachusetts
Country [4] 0 0
United States of America
State/province [4] 0 0
New York
Country [5] 0 0
United States of America
State/province [5] 0 0
Texas
Country [6] 0 0
Belgium
State/province [6] 0 0
Leuven
Country [7] 0 0
Germany
State/province [7] 0 0
Köln
Country [8] 0 0
Germany
State/province [8] 0 0
München
Country [9] 0 0
Israel
State/province [9] 0 0
Haifa
Country [10] 0 0
Israel
State/province [10] 0 0
Ramat Gan
Country [11] 0 0
Israel
State/province [11] 0 0
Tel Aviv
Country [12] 0 0
Poland
State/province [12] 0 0
Szczecin
Country [13] 0 0
Spain
State/province [13] 0 0
Barcelona
Country [14] 0 0
Spain
State/province [14] 0 0
Hospitalet deLlobregat
Country [15] 0 0
Sweden
State/province [15] 0 0
Lund
Country [16] 0 0
United Kingdom
State/province [16] 0 0
Cambridge
Country [17] 0 0
United Kingdom
State/province [17] 0 0
Edinburgh
Country [18] 0 0
United Kingdom
State/province [18] 0 0
London
Country [19] 0 0
United Kingdom
State/province [19] 0 0
Manchester
Country [20] 0 0
United Kingdom
State/province [20] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.
Trial website
https://clinicaltrials.gov/study/NCT00628251
Trial related presentations / publications
Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4.
Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidzinski M, Kim JW, Nam JH, Madry R, Hernandez C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol. 2020 Apr 10;38(11):1164-1174. doi: 10.1200/JCO.19.02745. Epub 2020 Feb 19.
Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016 Jun;27(6):1013-1019. doi: 10.1093/annonc/mdw133. Epub 2016 Mar 8.
Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6.
Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009 Mar;9(3):167-81. doi: 10.1038/nrc2583.
Public notes

Contacts
Principal investigator
Name 0 0
Jane Robertson, BSc, MBCHB, MD
Address 0 0
AstraZeneca
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00628251